MUSCAT:The initiative, a joint undertaking between the OIA, Ministry of Finance and Ministry of Health, in partnership with Saudi-based Oryx Isotopes, is aimed at strengthening national health security, advancing cancer diagnosis and treatment, and developing specialised healthcare industries.
The project will establish an integrated facility for producing radiopharmaceuticals, alongside a specialised calibration laboratory and research and development facilities, according to the OIA.
The radiopharmaceutical production facility will manufacture specialised medical products used in the diagnosis and early detection of cancer, cardiovascular and neurological diseases, as well as targeted radionuclide therapies.
Read More
- Oman crude oil price drops 33 cents
- Bank Muscat launches exclusive credit card and financing offers to celebrate Oman’s National Day
- Muscat Stock Exchange announces share allocation results for Asyad Shipping’s RO 65.4 million offering
- Oman’s hotel revenues fall 11.7% to RO 171.1 million by end of September
- Al Mouj Muscat scores triple win at International and Arabian Property Awards 2026
The initiative is expected to expand nuclear medicine services in Oman, facilitate the transfer of advanced technologies and develop national expertise in the specialised field.
Oman Nucleus will comprise three main components designed to support the development of the country’s radiopharmaceutical industry.
The first is an integrated production facility dedicated to manufacturing radiopharmaceuticals for diagnostic and therapeutic applications, including targeted treatments for certain diseases.
The second component is a specialised calibration laboratory that will calibrate radiation equipment in accordance with international standards. The facility will serve radiation measurement and protection requirements across the healthcare and industrial sectors.
The third component will comprise research and development facilities to support the development of new radiopharmaceuticals and targeted therapies, strengthening local research capabilities and technical expertise.
The project aims to strengthen national health security by establishing local production capabilities for specialised medical products and expanding access to advanced nuclear medicine services.
It will also contribute to increasing local content, transferring technology and developing Omani talent in radiopharmaceutical production, research and radiation measurement.
It is expected to create new investment opportunities in the pharmaceutical and healthcare industries, while opening prospects for exporting radiopharmaceutical products to regional markets.
